Strategic Expansion into Oceania
Avicanna Inc. has officially announced a significant milestone in its international growth strategy. The company’s majority-owned subsidiary, Santa Marta Golden Hemp SAS (SMGH), has successfully completed its first commercial export of CBG-dominant cannabis flower to Australia. This shipment represents a pivotal entry into the Australian medical cannabis market, further solidifying Avicanna’s position as a key player in the global plant-derived cannabinoid landscape.
This latest development marks the 21st international market for SMGH and the 24th global market for the broader Avicanna product portfolio. The move underscores the company’s commitment to scaling its operations and leveraging its proprietary genetics to meet the rising demand for standardized cannabinoid products internationally.
Quality Assurance and Operational Excellence
The successful export is the result of a concerted two-year effort by the company to align SMGH’s operations with international regulatory benchmarks. By investing heavily in process development, advanced infrastructure, and robust quality systems, Avicanna has ensured that its SMGH facility is capable of producing consistent, standardized cannabis flower at a commercial scale.
Central to this achievement is the facility’s adherence to Good Agricultural and Collection Practices (GACP) and stringent organic certification standards. These protocols are essential for providing active pharmaceutical ingredients (API) that meet the rigorous requirements of international pharmaceutical partners. The SMGH operational model benefits from equatorial cultivation conditions, which allow for year-round production cycles and high batch uniformity, critical factors for long-term reliability in the medical cannabis sector.
The Future of Cannabinoid Research
Beyond cultivation, this export highlights the effectiveness of Avicanna’s scientific platform. The inclusion of the company’s proprietary CBG cultivar in this shipment validates its ongoing focus on cannabinoid-specific chemotypes. As research into rare cannabinoids continues to accelerate, Avicanna’s ability to provide high-quality, traceable raw materials positions it as a preferred partner for international food, cosmetic, and pharmaceutical companies.
By continuing to prioritize traceability and compliance, Avicanna aims to maintain its momentum in existing markets while proactively identifying new regions for expansion. The Australia market entry is expected to serve as a cornerstone for future growth in the Asia-Pacific region, proving that the company’s vertically integrated model can successfully bridge the gap between South American cultivation and sophisticated global medical markets.
FAQ: People Also Ask
What is the significance of the SMGH export to Australia?
This marks Avicanna’s first commercial export of CBG-dominant cannabis flower to the Australian market, representing a new international footprint and demonstrating the scalability of the company’s standardized, organic-certified production model.
What types of products does SMGH produce?
SMGH specializes in providing high-quality, plant-derived cannabinoid-based products, including CBG, CBD, and THC-dominant cannabis flowers, which serve as active pharmaceutical ingredients for global medical, pharmaceutical, and consumer retail sectors.
Why does Avicanna use Colombia for its cultivation?
Colombia offers ideal equatorial conditions that allow for consistent, year-round cultivation. This environment supports reliable production cycles, cost efficiencies, and the ability to maintain the batch uniformity required for international medical-grade cannabis exports.
